Fresenius Group Overview
- The Health Care Group
-
Stories
-
![]()
Paul, the four-legged therapist
-
![]()
The History of Dialysis
-
![]()
’Remain true to your ideals’
-
![]()
Serving patients in Swaziland
-
![]()
Using protons to take on cancer
-
![]()
A little heart at the center of a complex surgery
-
![]()
On duty in disaster zones
-
![]()
More ‘Quality of Life’ in clinics
-
![]()
Ready to help the littlest ones
-
![]()
"I want to help others, so they won’t give up"
-
![]()
A polyclinic in Ghana
-
![]()
From a local pharmacy to a global corporation
-
- Investors
-
Media
![]()
Contact
Matthias Link
Vice President Corporate Communications
T: +49 (0) 6172 608-2872
matthias.link@fresenius.com - Careers
Paul, the four-legged therapist
The History of Dialysis
’Remain true to your ideals’
Serving patients in Swaziland
Using protons to take on cancer
A little heart at the center of a complex surgery
On duty in disaster zones
More ‘Quality of Life’ in clinics
Ready to help the littlest ones
"I want to help others, so they won’t give up"
A polyclinic in Ghana
From a local pharmacy to a global corporationMedia
Corporate Communications
Here you can find a variety of information:
- Press releases and Brief news
- Key dates for journalists
- Pictures, videos, audio files, press kits and other documents
- Social media channels
- Personal contacts
Our Corporate Communications team can be reached at pr-fre@fresenius.com.
“A pharmacy today? We need to expand it or add something new to it.” (Dr. Eduard Fresenius, Founder, 1912)
-
![]()
Webcast Import (ICS) Investor News (PDF) Transcript (PDF)December 07, 2018 - 08:00 AM | Bad Homburg, Germany
Conference Call - FY/2019 and Medium-Term Expectations
News
- Brief News
Fresenius Kabi receives positive CHMP opinion for MSB11022, a biosimilar candidate of adalimumab
Fresenius Kabi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022 a biosimilar candidate of Humira® (adalimumab)*. The European Commission (EC) will now decide on the approval of MSB11022 which is expected in Q2/ 2019.
*Humira® is a registered trademark of AbbVie Biotechnology Ltd.February 01, 2019Fresenius Kabi
![]()
-
![]()
Brief NewsFresenius Vamed adds new resort to network in Austria
VAMED Vitality World has taken over operation of a health resort in Austria’s Styria state. Operating under the new name of Spa Resort Styria in the town of Bad Waltersdorf, near Graz, the resort will offer health tourism for adults. Fresenius Vamed is the market leader in Austria, with about 3.2 million annual visitors to the company’s eight thermal spas and health resorts.
January 14, 2019Fresenius Vamed
-
Fresenius successfully places €1.0 billion in notes
January 10, 2019Fresenius
![]()
- Brief News
Fresenius wins award for compensatory time account calculator
Der Gesundheitskonzern Fresenius ist für seinen Langzeitkonto-Rechner mit dem „HR Excellence Award 2018“ in der Kategorie „Compensation & Benefits“ ausgezeichnet worden. Der Langzeitkonto-Rechner bietet den Mitarbeitern schnell und transparent Informationen über eingebrachte Beiträge, Auszeiten für die persönliche Weiterbildung oder die Pflege von Angehörigen sowie einen möglichen Vorruhestand. Mit den „HR Excellence Awards“ prämiert das Magazin „Human Resources Manager“ seit 2012 herausragende Projekte im Personalmanagement.
December 14, 2018Fresenius
![]()
- Brief News
PWC proposed as auditor for 2020
The Supervisory Board of Fresenius SE & Co. KGaA has decided to propose PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft as the auditor for the financial year 2020. The shareholders will decide on the appointment at the Annual General Meeting in 2020. New regulations provide for a regular rotation of the auditor, so Fresenius was not able to extend the existing mandate of KPMG AG Wirtschaftsprüfungsgesellschaft.
December 10, 2018Fresenius
![]()
-
![]()
![]()
-
![]()
Brief NewsFresenius Kabi receives FDA Drug Shortage Assistance Award
Fresenius Kabi has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA). The FDA recognized the role Fresenius Kabi played in helping mitigate a shortage of IV saline, specifically Sodium Chloride Injection USP, 0.9% in bags. The shortage was caused last year by supply disruptions at manufacturers affected by Hurricane Maria. The hurricane devastated Puerto Rico, where many companies produce medicines for U.S. hospitals.
December 03, 2018Fresenius Kabi
- Brief News
Fresenius Vamed wins awards for spa and wellness facilities
VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2018” at the World Spa Awards. Four VAMED Vitality World facilities – Geinberg5 Private Villas, Aqua Dome Therme Längenfeld, Therme Laa Hotel & Spa, all in Austria, and Aquaworld Resort Budapest in the Hungarian capital – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria and Hungary.
November 26, 2018Fresenius Vamed
Brief NewsFresenius training programs among the best in Germany
A recent study places Fresenius among the top 500 companies in terms of career training programs in Germany. Criteria used for judgement were the quality of supervision, in-house training, company engagement, success rate and innovative teaching methods. The companies were rated by the business magazine Capital and the internet portal, ausbildung.de. Fresenius received a best possible five-star rating for its on-the-job training and dual-studies, a combination of theory and on-the-job training, programs. The company trains more than 4,000 apprentices and dual-studies interns.
November 19, 2018Fresenius
-
![]()
![]()
-
![]()
Brief NewsFresenius Helios acquires private hospital operator in Colombia, expanding presence in Latin America
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has acquired Clínica Medellín and entered the attractive private hospital market in Colombia. Clínica Medellín operates two centrally located hospitals in Medellín, a major city of 2.5 million people. The two facilities have a total of about 185 beds. The total investment for Clínica Medellín is more than €50 million. Following Quirónsalud's entry into Peru last year, this is another step in strengthening the company’s presence in Latin America’s growing and consolidating hospital markets. Fresenius Helios expects the transaction to close in Q1 2019, pending anti-trust and regulatory clearance.
October 30, 2018Fresenius Helios
-
![]()
![]()
-
![]()
![]()
- Brief News
Fresenius Kabi opens compounding center in Canada
Fresenius Kabi has opened a new state-of-the-art compounding center in Canada. It involves an investment of 11 million Canadian dollars (more than €7 million), and the new site expands the company’s presence in Mississauga, Ontario. Fresenius Kabi is responding to increasing demand for large batches of compounded medications for patients in Canadian hospitals, and the 35,000-square-foot (3,300-square-meter) compounding center has the capacity to expand. The new facility is expected to employ 70 people by 2022.
October 16, 2018Fresenius Kabi
Brief NewsFresenius Kabi biosimilar candidate meets primary endpoints in the two pivotal clinical studies
Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11455, a biosimilar candidate for Neulasta® (pegfilgrastim), has met its primary endpoints in the two pivotal clinical studies. For more information please see the website of Fresenius Kabi.
October 09, 2018Fresenius Kabi
-
![]()
![]()
-
![]()
Brief News2019 DRG inflator for German hospitals set at 2.65%
The price increase for hospital services in Germany has been set at 2.65% for 2019. This is in line with the level of past years.
September 17, 2018Fresenius Helios
Contact
Do you have other questions or need any more information?
Your contact:
Matthias Link
Vice President Corporate Communications
T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Social Media
-
Gehe zu Facebook
I hereby express my consent to the processing of my personal data for the usage of the social Feeds according to paragraph 4 of the "Privacy Policy and Declaration of Consent".
I consent -
Gehe zu Twitter
I hereby express my consent to the processing of my personal data for the usage of the social Feeds according to paragraph 4 of the "Privacy Policy and Declaration of Consent".
I consent -
Gehe zu Youtube
- Gehe zu LinkedIn
- Gehe zu Xing
Contact us
Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com
Contact
